Cargando…
TIGIT-based immunotherapeutics in lung cancer
In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small cell and small cell lung cancer, a disease transformed by th...
Autores principales: | Patel, Akshay J, Middleton, Gary W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266577/ https://www.ncbi.nlm.nih.gov/pubmed/37325585 http://dx.doi.org/10.1093/immadv/ltad009 |
Ejemplares similares
-
Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma
por: Middleton, Gary
Publicado: (2020) -
Upcoming immunotherapeutic combinations for B-cell lymphoma
por: Greve, Patrick, et al.
Publicado: (2021) -
A glutamine ‘tug-of-war’: targets to manipulate glutamine metabolism for cancer immunotherapy
por: Pallett, Laura J, et al.
Publicado: (2021) -
A summary of current NKG2D-based CAR clinical trials
por: Curio, Sophie, et al.
Publicado: (2021) -
An overview of CAR T-cell clinical trial activity to 2021
por: Adami, Antonella, et al.
Publicado: (2021)